Dimitri M Kullmann

List of Publications by Year
in descending order

308	17,158	13099 68	17592 121
papers	citations	h-index	g-index

333	333	333	15970
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Translating genetic and functional data into clinical practice: a series of 223 families with myotonia. Brain, 2022, 145, 607-620.	7.6	8
2	114â€... Neuro-critical care: a 4-year experience. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A46.2-A46.	1.9	0
3	Nicotinic receptor activation induces NMDA receptor independent longâ€term potentiation of glutamatergic signalling in hippocampal oriens interneurons. Journal of Physiology, 2021, 599, 667-676.	2.9	11
4	A retrospective cohort study of super-refractory status epilepticus in a tertiary neuro-ICU setting. Seizure: the Journal of the British Epilepsy Association, 2021, 85, 90-94.	2.0	4
5	Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis. BMJ Neurology Open, 2021, 3, e000096.	1.6	4
6	Impaired Preâ€Motor Circuit Activity and Movement in a Drosophila Model of <scp>KCNMA1</scp>â€Linked Dyskinesia. Movement Disorders, 2021, 36, 1158-1169.	3.9	15
7	dCas9-Based Scn1a Gene Activation Restores Inhibitory Interneuron Excitability and Attenuates Seizures in Dravet Syndrome Mice. Molecular Therapy, 2020, 28, 235-253.	8.2	135
8	Optogenetic and chemogenetic therapies for epilepsy. Neuropharmacology, 2020, 168, 107751.	4.1	62
9	In vivo CRISPRa decreases seizures and rescues cognitive deficits in a rodent model of epilepsy. Brain, 2020, 143, 891-905.	7.6	79
10	A genetically encoded fluorescent sensor for in vivo imaging of GABA. Nature Methods, 2019, 16, 763-770.	19.0	242
11	AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders. Nature Communications, 2019, 10, 3094.	12.8	150
12	Editorial. Brain, 2019, 142, 2169-2169.	7.6	0
13	Editorial. Brain, 2019, 142, 1847-1847.	7.6	0
14	Novel therapies for epilepsy in the pipeline. Epilepsy and Behavior, 2019, 97, 282-290.	1.7	28
15	Editorial. Brain, 2019, 142, 2545-2545.	7.6	0
16	Glycine receptor autoantibodies disrupt inhibitory neurotransmission. Brain, 2019, 142, 3398-3410.	7.6	47
17	Editorial. Brain, 2019, 142, 3315-3315.	7.6	0
18	Biallelic mutations in neurofascin cause neurodevelopmental impairment and peripheral demyelination. Brain, 2019, 142, 2948-2964.	7.6	43

#	Article	IF	Citations
19	Editorial. Brain, 2019, 142, 2893-2894.	7.6	0
20	Cell-Free Expression of Sodium Channel Domains for Pharmacology Studies. Noncanonical Spider Toxin Binding Site in the Second Voltage-Sensing Domain of Human Nav1.4 Channel. Frontiers in Pharmacology, 2019, 10, 953.	3.5	4
21	Editorial. Brain, 2019, 142, 1165-1165.	7.6	0
22	Editorial. Brain, 2019, 142, 1489-1490.	7.6	0
23	PDXK mutations cause polyneuropathy responsive to pyridoxal 5â€²â€phosphate supplementation. Annals of Neurology, 2019, 86, 225-240.	5.3	54
24	Designer receptor technology for the treatment of epilepsy. EBioMedicine, 2019, 43, 641-649.	6.1	38
25	Hippocampalâ€“prefrontal coherence mediates working memory and selective attention at distinct frequency bands and provides a causal link between schizophrenia and its risk gene GRIA1. Translational Psychiatry, 2019, 9, 142.	4.8	51
26	Olanzapine: A potent agonist at the hM4D(Gi) DREADD amenable to clinical translation of chemogenetics. Science Advances, 2019, 5, eaaw1567.	10.3	44
27	KCC2 overexpression prevents the paradoxical seizure-promoting action of somatic inhibition. Nature Communications, 2019, 10, 1225.	12.8	75
28	Loss of Frrs1l disrupts synaptic AMPA receptor function, and results in neurodevelopmental, motor, cognitive and electrographical abnormalities. DMM Disease Models and Mechanisms, 2019, 12, .	2.4	22
29	Mutations in the Neuronal Vesicular SNARE VAMP2 Affect Synaptic Membrane Fusion and Impair Human Neurodevelopment. American Journal of Human Genetics, 2019, 104, 721-730.	6.2	88
30	Editorial. Brain, 2019, 142, 833-833.	7.6	1
31	Editorial. Brain, 2019, 142, 227-227.	7.6	0
32	Editorial. Brain, 2019, 142, 489-489.	7.6	0
33	Epilepsy Gene Therapy Using an Engineered Potassium Channel. Journal of Neuroscience, 2019, 39, 3159-3169.	3.6	78
34	Rhombencephalitis and Myeloradiculitis Caused by a European Subtype of Tick-Borne Encephalitis Virus. Emerging Infectious Diseases, 2019, 25, 2317-2319.	4.3	2
35	Myotonia in a patient with a mutation in an S4 arginine residue associated with hypokalaemic periodic paralysis and a concomitant synonymous CLCN1 mutation. Scientific Reports, 2019, 9, 17560.	3.3	13
36	Can N-Methyl-D-Aspartate Receptor Hypofunction in Schizophrenia Be Localized to an Individual Cell Type?. Frontiers in Psychiatry, 2019, 10, 835.	2.6	26

#	Article	IF	Citations
37	GABAergic Interneurons in Seizures: Investigating Causality With Optogenetics. Neuroscientist, 2019, 25, 344-358.	3.5	71
38	Editorial. Brain, 2019, 142, 1-1.	7.6	11
39	Dendritic NMDA receptors in parvalbumin neurons enable strong and stable neuronal assemblies. ELife, 2019, 8, .	6.0	42
40	Spider toxin inhibits gating pore currents underlying periodic paralysis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4495-4500.	7.1	24
41	Dysfunction of NaV1.4, a skeletal muscle voltage-gated sodium channel, in sudden infant death syndrome: a case-control study. Lancet, The, 2018, 391, 1483-1492.	13.7	63
42	Editorial. Brain, 2018, 141, 323-323.	7.6	0
43	Imaging pathological activities of human brain tissue in organotypic culture. Journal of Neuroscience Methods, 2018, 298, 33-44.	2.5	36
44	Editorial. Brain, 2018, 141, 1-1.	7.6	6
45	Editorial. Brain, 2018, 141, 1235-1235.	7.6	0
46	Editorial. Brain, 2018, 141, 935-935.	7.6	0
47	Editorial. Brain, 2018, 141, 621-621.	7.6	0
48	Semiology, clustering, periodicity and natural history of seizures in an experimental occipital cortical epilepsy model. DMM Disease Models and Mechanisms, 2018, 11, .	2.4	9
49	Editorial. Brain, 2018, 141, 3279-3279.	7.6	0
50	Editorial. Brain, 2018, 141, 1887-1887.	7.6	0
51	Editorial. Brain, 2018, 141, 2823-2823.	7.6	0
52	Editorial. Brain, 2018, 141, 3083-3083.	7.6	0
53	Optogenetic induction of the schizophrenia-related endophenotype of ventral hippocampal hyperactivity causes rodent correlates of positive and cognitive symptoms. Scientific Reports, 2018, 8, 12871.	3.3	22
54	Editorial. Brain, 2018, 141, 2231-2231.	7.6	0

#	Article	IF	Citations
55	The Enlightened Brain: Novel Imaging Methods Focus on Epileptic Networks at Multiple Scales. Frontiers in Cellular Neuroscience, 2018, 12, 82.	3.7	13
56	Biochemical autoregulatory gene therapy for focal epilepsy. Nature Medicine, 2018, 24, 1324-1329.	30.7	47
57	Application of long single-stranded DNA donors in genome editing: generation and validation of mouse mutants. BMC Biology, 2018, 16, 70.	3.8	74
58	Gene-Environment Interaction in a Conditional NMDAR-Knockout Model of Schizophrenia. Frontiers in Behavioral Neuroscience, 2018, 12, 332.	2.0	7
59	Analogue closed-loop optogenetic modulation of hippocampal pyramidal cells dissociates gamma frequency and amplitude. ELife, 2018, 7, .	6.0	15
60	Editorial. Brain, 2018, 141, 2533.	7.6	0
61	Changes in the severity and subtype of Guillain-BarrÃ© syndrome admitted to a specialist Neuromedical ICU over a 25Âyear period. Journal of Neurology, 2017, 264, 564-569.	3.6	9
62	Tâ€type calcium channels contribute to NMDA receptor independent synaptic plasticity in hippocampal regularâ€spiking oriensâ€alveus interneurons. Journal of Physiology, 2017, 595, 3449-3458.	2.9	17
63	CD8+ encephalitis: a severe but treatable HIV-related acute encephalopathy. Practical Neurology, 2017, 17, 42-46.	1.1	15
64	Kv1.1 channelopathy abolishes presynaptic spike width modulation by subthreshold somatic depolarization. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2395-2400.	7.1	31
65	Activity Clamp Provides Insights into Paradoxical Effects of the Anti-Seizure Drug Carbamazepine. Journal of Neuroscience, 2017, 37, 5484-5495.	3.6	10
66	Progressive Motor Neuron Pathology and the Role of Astrocytes in a Human Stem Cell Model of VCP-Related ALS. Cell Reports, 2017, 19, 1739-1749.	6.4	146
67	De novo KCNA2 mutations cause hereditary spastic paraplegia. Annals of Neurology, 2017, 81, 326-328.	5.3	13
68	Editorial. Brain, 2017, 140, 1-1.	7.6	13
69	Mutations in Membrin/ GOSR2 Reveal Stringent Secretory Pathway Demands of Dendritic Growth and Synaptic Integrity. Cell Reports, 2017, 21, 97-109.	6.4	29
70	Clinical, pathological and functional characterization of riboflavin-responsive neuropathy. Brain, 2017, 140, 2820-2837.	7.6	64
71	Editorial. Brain, 2017, 140, 2521-2521.	7.6	0
72	Editorial. Brain, 2017, 140, 2253-2253.	7.6	0

#	Article	IF	Citations
73	Personalized translational epilepsy research â€" Novel approaches and future perspectives. Epilepsy and Behavior, 2017, 76, 7-12.	1.7	14
74	Personalized translational epilepsy research â€" Novel approaches and future perspectives. Epilepsy and Behavior, 2017, 76, 13-18.	1.7	26
75	Focal cortical seizures start as standing waves and propagate respecting homotopic connectivity. Nature Communications, 2017, 8, 217.	12.8	67
76	Pathogenic potential of antibodies to the <scp>GABA_B</scp> receptor. Epilepsia Open, 2017, 2, 355-359.	2.4	30
77	Editorial. Brain, 2017, 140, 1817-1817.	7.6	2
78	PO006â€...Encephalitis on the neuro-icu: changing patterns. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A14.2-A14.	1.9	0
79	Editorial. Brain, 2017, 140, 1171-1171.	7.6	1
80	PO221â€...Pathological mechanisms of glycine receptor antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A70.2-A70.	1.9	0
81	PO007â€...Neuro-critical care: an 11-year experience. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A14.3-A14.	1.9	0
82	Editorial. Brain, 2017, 140, 2763-2763.	7.6	0
83	PO190â€...Anti-musk positive myasthenia gravis at a tertiary centre. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A61.3-A61.	1.9	0
84	Editorial. Brain, 2017, 140, 2065-2065.	7.6	0
85	Editorial. Brain, 2017, 140, 515-515.	7.6	0
86	Genetic neurological channelopathies: molecular genetics and clinical phenotypes. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2015-311233.	1.9	71
87	Editorial. Brain, 2016, 139, 3051-3051.	7.6	0
88	Modulation of axonal signalling in type 1 episodic ataxia. Lancet, The, 2016, 387, S104.	13.7	0
89	Knockout of NMDA-receptors from parvalbumin interneurons sensitizes to schizophrenia-related deficits induced by MK-801. Translational Psychiatry, 2016, 6, e778-e778.	4.8	91
90	Editorial. Brain, 2016, 139, 1311-1311.	7.6	0

#	Article	IF	Citations
91	Lentiviral expression of GAD67 and CCK promoter-driven opsins to target interneuronsin vitroandin vivo. Journal of Gene Medicine, 2016, 18, 27-37.	2.8	1
92	Editorial. Brain, 2016, 139, 2335-2335.	7.6	0
93	Action potential broadening in a presynaptic channelopathy. Nature Communications, 2016, 7, 12102.	12.8	70
94	Editorial. Brain, 2016, 139, 2103-2103.	7.6	0
95	Editorial. Brain, 2016, 139, 2815-2815.	7.6	1
96	Editorial. Brain, 2016, 139, 1621-1621.	7.6	0
97	Editorial. Brain, 2016, 139, 1001-1001.	7.6	0
98	Editorial. Brain, 2016, 139, 1865-1865.	7.6	0
99	Autoimmune synaptopathies. Nature Reviews Neuroscience, 2016, 17, 103-117.	10.2	81
100	Editorial. Brain, 2016, 139, 1-1.	7.6	24
101	Editorial. Brain, 2016, 139, 303-303.	7.6	1
102	In vivoimpact of presynaptic calcium channel dysfunction on motor axons in episodic ataxia type 2. Brain, 2016, 139, 380-391.	7.6	11
103	Editorial. Brain, 2016, 139, 641-641.	7.6	0
104	Optogenetic approaches to treat epilepsy. Journal of Neuroscience Methods, 2016, 260, 215-220.	2.5	44
105	Study on presynaptic action potential waveform in hippocampal neuronal culture models of episodic ataxia type 1 using scanning ion conductance microscopy. Journal of the Neurological Sciences, 2015, 357, e233.	0.6	0
106	Presynaptic channelopathies causing ataxia and migraine. Journal of the Neurological Sciences, 2015, 357, e493.	0.6	0
107	Expanding the Phenotype and Genetic Defects Associated with the <scp>GOSR</scp>2 Gene. Movement Disorders Clinical Practice, 2015, 2, 271-273.	1.5	21
108	Editorial. Brain, 2015, 138, 237-237.	7.6	0

#	Article	IF	Citations
109	Editorial. Brain, 2015, 138, 1-1.	7.6	30
110	Editorial. Brain, 2015, 138, 1443-1443.	7.6	0
111	Editorial. Brain, 2015, 138, 1765-1765.	7.6	0
112	Editorial. Brain, 2015, 138, 2113-2113.	7.6	0
113	Editorial. Brain, 2015, 138, 2801-2801.	7.6	0
114	Lambert-Eaton syndrome IgG inhibits transmitter release via P/Q Ca ²⁺ channels. Neurology, 2015, 84, 575-579.	1.1	16
115	Clinical relevance of serum antibodies to extracellularN-methyl-d-aspartate receptor epitopes. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 708-713.	1.9	97
116	Hypokalemic periodic paralysis: an omega pore mutation affects inactivation. Channels, 2015, 9, 161-161.	2.8	2
117	Editorial. Brain, 2015, 138, 827-827.	7.6	0
118	Mutations in SLC12A5 in epilepsy of infancy with migrating focal seizures. Nature Communications, 2015, 6, 8038.	12.8	160
119	Editorial. Brain, 2015, 138, 3131-3131.	7.6	0
120	Induction of Anti-Hebbian LTP in CA1 Stratum Oriens Interneurons: Interactions between Group I Metabotropic Glutamate Receptors and M1 Muscarinic Receptors. Journal of Neuroscience, 2015, 35, 13542-13554.	3.6	28
121	The clinical and genetic heterogeneity of paroxysmal dyskinesias. Brain, 2015, 138, 3567-3580.	7.6	129
122	CHAPTER 10. Optogenetic and Chemogenetic Tools for Drug Discovery in Schizophrenia. RSC Drug Discovery Series, 2015, , 234-272.	0.3	1
123	Release of Neurotransmitters. , 2014, , 443-488.		11
124	Gene therapy in epilepsyâ€"is it time for clinical trials?. Nature Reviews Neurology, 2014, 10, 300-304.	10.1	67
125	Editorial. Brain, 2014, 137, 307-307.	7.6	0
126	Editorial. Brain, 2014, 137, 973-973.	7.6	0

#	Article	IF	Citations
127	Editorial. Brain, 2014, 137, 1273-1273.	7.6	0
128	Editorial. Brain, 2014, 137, 1853-1853.	7.6	0
129	Editorial. Brain, 2014, 137, 2109-2109.	7.6	0
130	Editorial. Brain, 2014, 137, 3099-3099.	7.6	0
131	Editorial. Brain, 2014, 137, 645-645.	7.6	0
132	Editorial. Brain, 2014, 137, 2871-2871.	7.6	0
133	Editorial. Brain, 2014, 137, 1569-1569.	7.6	0
134	PATHOLOGICAL MECHANISMS OF GLYCINE RECEPTOR ANTIBODIES. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.12-e4.	1.9	0
135	Long-term potentiation in hippocampal oriens interneurons: postsynaptic induction, presynaptic expression and evaluation of candidate retrograde factors. Philosophical Transactions of the Royal Society B: Biological Sciences, 2014, 369, 20130133.	4.0	21
136	CHANGING FORMS OF GUILLAIN-BARRÃ© SYNDROME IN NEURO-ICU. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.85-e4.	1.9	0
137	Chemicalâ€“genetic attenuation of focal neocortical seizures. Nature Communications, 2014, 5, 3847.	12.8	118
138	Oscillatory multiplexing of population codes for selective communication in the mammalian brain. Nature Reviews Neuroscience, 2014, 15, 111-122.	10.2	314
139	Pathological mechanisms in patients with antibodies to glycine receptors. Journal of Neuroimmunology, 2014, 275, 97.	2.3	0
140	Editorial. Brain, 2014, 137, 2399-2399.	7.6	0
141	Just a graze? Cephalic tetanus presenting as a stroke mimic. Practical Neurology, 2014, 14, 39-41.	1.1	6
142	Myasthenia gravis â€“ treatment of acute severe exacerbations in the intensive care unit results in a favourable longâ€term prognosis. European Journal of Neurology, 2014, 21, 171-173.	3.3	25
143	Myasthenia gravis and neuromyelitis opica: A causal link. Multiple Sclerosis and Related Disorders, 2013, 2, 233-237.	2.0	16
144	Differential triggering of spontaneous glutamate release by P/Q-, N- and R-type Ca2+ channels. Nature Neuroscience, 2013, 16, 1754-1763.	14.8	130

#	Article	IF	Citations
145	Slow channel congenital myasthenic syndrome responsive to a combination of fluoxetine and salbutamol. Muscle and Nerve, 2013, 47, 279-282.	2.2	23
146	Nanoscale-Targeted Patch-Clamp Recordings of Functional Presynaptic Ion Channels. Neuron, 2013, 79, 1067-1077.	8.1	103
147	Thymectomy: role in the treatment of myasthenia gravis. Journal of Neurology, 2013, 260, 1798-1801.	3.6	46
148	NMDA receptor-dependent function and plasticity in inhibitory circuits. Neuropharmacology, 2013, 74, 23-31.	4.1	38
149	Cortical inhibition, pH and cell excitability in epilepsy: what are optimal targets for antiepileptic interventions?. Journal of Physiology, 2013, 591, 765-774.	2.9	64
150	Clinical, genetic, neurophysiological and functional study of new mutations in episodic ataxia type 1. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1107-1112.	1.9	46
151	LAMBERT EATON MYASTHENIC SYNDROME ANTIBODIES DECREASE SYNAPTIC VESICLE EXOCYTOSIS IN NEURONAL CULTURES. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.151-e2.	1.9	0
152	JUST A GRAZE?. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.159-e2.	1.9	0
153	Gene therapy in status epilepticus. Epilepsia, 2013, 54, 43-45.	5.1	9
154	Independent Regulation of Basal Neurotransmitter Release Efficacy by Variable Ca2+ Influx and Bouton Size at Small Central Synapses. PLoS Biology, 2012, 10, e1001396.	5.6	58
155	Efficient â€œCommunication through Coherenceâ€•Requires Oscillations Structured to Minimize Interference between Signals. PLoS Computational Biology, 2012, 8, e1002760.	3.2	73
156	170â€…Diaphragmatic weakness following thymectomy: due to myasthenia gravis or phrenic nerve injury?. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.127-e1.	1.9	1
157	Late recurrent thymoma in myasthenia gravis: a case series: Table 1. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 1030-1031.	1.9	9
158	PRRT2 gene mutations. Neurology, 2012, 79, 2115-2121.	1.1	159
159	171â€…Myasthenic crisis in the intensive care unit: a 10-year review. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.128-e1.	1.9	2
160	172â€…An unusual case of congenital myasthenic syndrome: the mechanism for treatment response. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.129-e1.	1.9	0
161	N-methyl-D-aspartate receptor antibody-mediated encephalitis. British Journal of Hospital Medicine (London, England: 2005), 2012, 73, 472-473.	0.5	0
162	Optogenetic and Potassium Channel Gene Therapy in a Rodent Model of Focal Neocortical Epilepsy. Science Translational Medicine, 2012, 4, 161ra152.	12.4	216

#	Article	IF	Citations
163	Plasticity of Inhibition. Neuron, 2012, 75, 951-962.	8.1	198
164	In vivo loss of slow potassium channel activity in individuals with benign familial neonatal epilepsy in remission. Brain, 2012, 135, 3144-3152.	7.6	18
165	Vasculitis of the central and peripheral nervous system mimicking brain death. Clinical Neurology and Neurosurgery, 2012, 114, 399-401.	1.4	1
166	The Mother of All Battles 20 years on: is LTP expressed preâ€•or postsynaptically?. Journal of Physiology, 2012, 590, 2213-2216.	2.9	21
167	Oscillatory dynamics in the hippocampus support dentate gyrusâ€“CA3 coupling. Nature Neuroscience, 2012, 15, 763-768.	14.8	95
168	Mapping out hippocampal inhibition. Nature Neuroscience, 2012, 15, 346-347.	14.8	1
169	Ionotropic receptors at hippocampal mossy fibers: roles in axonal excitability, synaptic transmission, and plasticity. Frontiers in Neural Circuits, 2012, 6, 112.	2.8	17
170	LTP and LTD in cortical GABAergic interneurons: Emerging rules and roles. Neuropharmacology, 2011, 60, 712-719.	4.1	83
171	Short- and long-term depression at glutamatergic synapses on hippocampal interneurons by group I mGluR activation. Neuropharmacology, 2011, 60, 748-756.	4.1	28
172	Interneurons go plastic. Neuropharmacology, 2011, 60, 711.	4.1	5
173	GABA_A receptor mutations in epilepsy (Commentary on Lachanceâ€Touchette et al.). European Journal of Neuroscience, 2011, 34, 235-236.	2.6	3
174	Interneuron networks in the hippocampus. Current Opinion in Neurobiology, 2011, 21, 709-716.	4.2	81
175	Ih-mediated depolarization enhances the temporal precision of neuronal integration. Nature Communications, 2011, 2, 199.	12.8	54
176	Group I mGluR Agonist-Evoked Long-Term Potentiation in Hippocampal Oriens Interneurons. Journal of Neuroscience, 2011, 31, 5777-5781.	3.6	42
177	What's wrong with the amygdala in temporal lobe epilepsy?. Brain, 2011, 134, 2800-2801.	7.6	27
178	Alternative Splicing Modulates Inactivation of Type 1 Voltage-gated Sodium Channels by Toggling an Amino Acid in the First S3-S4 Linker. Journal of Biological Chemistry, 2011, 286, 36700-36708.	3.4	37
179	Nongenetic factors influence severity of episodic ataxia type 1 in monozygotic twins. Neurology, 2011, 76, 490-490.	1.1	1
180	Anti-N-methyl-D-aspartate receptor antibodies: A potentially treatable cause of encephalitis in the intensive care unit. Critical Care Medicine, 2010, 38, 679-682.	0.9	88

#	Article	IF	Citations
181	N-methyl-D-aspartate limbic encephalitis: Diagnosis should respect well-recognized criteria. Critical Care Medicine, 2010, 38, 1615-1616.	0.9	1
182	Central nervous system histoplasmosis in an immunocompetent patient. Journal of Neurology, 2010, 257, 1931-1933.	3.6	11
183	Tonic GABAA receptor-mediated signaling. Epilepsia, 2010, 51, 14-14.	5.1	2
184	How much inhibition in an epileptiform burst?. Journal of Physiology, 2010, 588, 17-18.	2.9	3
185	Genetic and functional characterisation of the P/Q calcium channel in episodic ataxia with epilepsy. Journal of Physiology, 2010, 588, 1905-1913.	2.9	85
186	Neurological channelopathies: new insights into disease mechanisms and ion channel function. Journal of Physiology, 2010, 588, 1823-1827.	2.9	95
187	Presynaptic GABAA receptors enhance transmission and LTP induction at hippocampal mossy fiber synapses. Nature Neuroscience, 2010, 13, 431-438.	14.8	102
188	A 'sustain pedal' in the hippocampus?. Nature Neuroscience, 2010, 13, 146-148.	14.8	5
189	Spike-timing dependent plasticity in inhibitory circuits. Frontiers in Synaptic Neuroscience, 2010, 2, 8.	2.5	61
190	PONM09 Thymectomy: its role in the management of myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e62-e63.	1.9	0
191	PONM08 Late recurrent thymoma: a case series. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e62-e62.	1.9	0
192	Nongenetic factors influence severity of episodic ataxia type 1 in monozygotic twins. Neurology, 2010, 75, 367-372.	1.1	40
193	PAW31 Clinical and genetic spectrum of the episodic ataxias: the UK perspective. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e32-e32.	1.9	1
194	Nerve excitability studies characterize KV1.1 fast potassium channel dysfunction in patients with episodic ataxia type 1. Brain, 2010, 133, 3530-3540.	7.6	87
195	Neurological Channelopathies. Annual Review of Neuroscience, 2010, 33, 151-172.	10.7	109
196	N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain, 2010, 133, 1655-1667.	7.6	900
197	Myasthenia and related disorders of the neuromuscular junction. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 850-857.	1.9	41
198	Oscillations and Filtering Networks Support Flexible Routing of Information. Neuron, 2010, 67, 308-320.	8.1	231

#	Article	IF	Citations
199	Neurological Manifestation of Vitamin B12 Deficiency. American Journal of Medicine, 2010, 123, e1-e2.	1.5	4
200	Sodium channel mutations and epilepsy: Association and causation. Experimental Neurology, 2010, 226, 8-10.	4.1	2
201	The Functional Effect of R1648H, a Sodium Channel Mutation that Causes Generalized Epilepsy with Febrile Seizures Plus in Splice Variants of SCN1A. Biophysical Journal, 2010, 98, 309a.	0.5	0
202	Open letter to prime minister David Cameron and health secretary Andrew Lansley. BMJ: British Medical Journal, 2010, 341, c6466-c6466.	2.3	21
203	Dysfunction of the CaV2.1 calcium channel in cerebellar ataxias. F1000 Biology Reports, 2010, 2, .	4.0	11
204	Large scale calcium channel gene rearrangements in episodic ataxia and hemiplegic migraine: implications for diagnostic testing. Journal of Medical Genetics, 2009, 46, 786-791.	3.2	56
205	Role of Ionotropic Glutamate Receptors in Long-Term Potentiation in Rat Hippocampal CA1 Oriens-Lacunosum Moleculare Interneurons. Journal of Neuroscience, 2009, 29, 939-950.	3.6	85
206	Outwardly Rectifying Tonically Active GABA_AReceptors in Pyramidal Cells Modulate Neuronal Offset, Not Gain. Journal of Neuroscience, 2009, 29, 15341-15350.	3.6	111
207	Synapsin- and Actin-Dependent Frequency Enhancement in Mouse Hippocampal Mossy Fiber Synapses. Cerebral Cortex, 2009, 19, 511-523.	2.9	20
208	Sodium channelopathy of peripheral nerve: tightening the genotype-phenotype relationship. Brain, 2009, 132, 1690-1692.	7.6	2
209	Voltage sensor charge loss accounts for most cases of hypokalemic periodic paralysis. Neurology, 2009, 72, 1544-1547.	1.1	160
210	A PATIENT WITH EPISODIC ATAXIA AND PARAMYOTONIA CONGENITA DUE TO MUTATIONS IN KCNA1 AND SCN4A. Neurology, 2009, 73, 993-995.	1.1	9
211	Density functional and spectroscopic studies of nitrogen inversion in substituted dizocilpines. Journal of Physical Organic Chemistry, 2009, 22, 607-612.	1.9	1
212	Computational Sophistication at a Single GABAergic Connection. Neuron, 2009, 63, 716-718.	8.1	1
213	Clinical neurophysiology of the episodic ataxias: Insights into ion channel dysfunction in vivo. Clinical Neurophysiology, 2009, 120, 1768-1776.	1.5	40
214	Episodic ataxia type 1 mutations differentially affect neuronal excitability and transmitter release. DMM Disease Models and Mechanisms, 2009, 2, 612-619.	2.4	38
215	Electric Fields Due to Synaptic Currents Sharpen Excitatory Transmission. Science, 2008, 319, 1845-1849.	12.6	69
216	Roles of distinct glutamate receptors in induction of antiâ€Hebbian longâ€term potentiation. Journal of Physiology, 2008, 586, 1481-1486.	2.9	40

#	Article	IF	Citations
217	Benign neonatal convulsions and spontaneous network activity in the developing brain: is there a link?. Journal of Physiology, 2008, 586, 5281-5281.	2.9	3
218	Premature stop codons in a facilitating EF-hand splice variant of CaV2.1 cause episodic ataxia type 2. Neurobiology of Disease, 2008, 32, 10-15.	4.4	24
219	D.P.2.09 Non-genomic effects of sex hormones on ClC-1 may contribute to gender differences in myotonia congenita. Neuromuscular Disorders, 2008, 18, 745.	0.6	0
220	D.P.2.12 Episodic ataxia type 1 in identical twins. Neuromuscular Disorders, 2008, 18, 746.	0.6	0
221	Non-genomic effects of sex hormones on CLC-1 may contribute to gender differences in myotonia congenita. Neuromuscular Disorders, 2008, 18, 869-872.	0.6	32
222	Analog Modulation of Mossy Fiber Transmission Is Uncoupled from Changes in Presynaptic Ca²⁺. Journal of Neuroscience, 2008, 28, 7765-7773.	3.6	60
223	Target-Cell Specificity of Kainate Autoreceptor and Ca²⁺-Store-Dependent Short-Term Plasticity at Hippocampal Mossy Fiber Synapses. Journal of Neuroscience, 2008, 28, 13139-13149.	3.6	69
224	Chloride channel myotonia: exon 8 hot-spot for dominant-negative interactions. Brain, 2007, 130, 3265-3274.	7.6	106
225	Cholinergic Axons Modulate GABAergic Signaling among Hippocampal Interneurons via Postsynaptic Â7 Nicotinic Receptors. Journal of Neuroscience, 2007, 27, 5683-5693.	3.6	68
226	Anti-Hebbian Long-Term Potentiation in the Hippocampal Feedback Inhibitory Circuit. Science, 2007, 315, 1262-1266.	12.6	219
227	NMDA receptorâ€dependent longâ€term potentiation in mouse hippocampal interneurons shows a unique dependence on Ca²⁺/calmodulinâ€dependent kinases. Journal of Physiology, 2007, 584, 885-894.	2.9	56
228	Long-term synaptic plasticity in hippocampal interneurons. Nature Reviews Neuroscience, 2007, 8, 687-699.	10.2	270
229	Episodic ataxia type 1: A neuronal potassium channelopathy. Neurotherapeutics, 2007, 4, 258-266.	4.4	106
230	Epileptogenesis Is Associated With Enhanced Glutamatergic Transmission in the Perforant Path. Journal of Neurophysiology, 2006, 95, 1213-1220.	1.8	50
231	Episodic ataxia type 1 mutations in theKCNA1gene impair the fast inactivation properties of the human potassium channels Kv1.4-1.1/Kvî²1.1 and Kv1.4-1.1/Kvî²1.2. European Journal of Neuroscience, 2006, 24, 3073-3083.	2.6	50
232	Presynaptic fluctuations and release-independent depression. Nature Neuroscience, 2006, 9, 1091-1093.	14.8	10
233	Dysfunction of the brain calcium channel CaV2.1 in absence epilepsy and episodic ataxiaâ€"authors' response. Brain, 2005, 128, E33-E33.	7.6	2
234	Presynaptic, extrasynaptic and axonal GABAA receptors in the CNS: where and why?. Progress in Biophysics and Molecular Biology, 2005, 87, 33-46.	2.9	193

#	Article	IF	Citations
235	Inherited Channelopathies of the CNS: Lessons for Clinical Neurology. , 2005, , 293-302.		0
236	Andersenâ€“Tawil syndrome. Neurology, 2005, 65, 1083-1089.	1.1	77
237	Catastrophic primary antiphospholipid syndrome presenting as status epilepticus. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1607-1608.	1.9	5
238	Multiple and Plastic Receptors Mediate Tonic GABAA Receptor Currents in the Hippocampus. Journal of Neuroscience, 2005, 25, 10016-10024.	3.6	227
239	Another migraine gene. Lancet, The, 2005, 366, 345-346.	13.7	15
240	Late-onset episodic ataxia type 2 due to an in-frame insertion in CACNA1A. Neurology, 2005, 65, 944-946.	1.1	52
241	Hebbian LTP in feed-forward inhibitory interneurons and the temporal fidelity of input discrimination. Nature Neuroscience, 2005, 8, 916-924.	14.8	149
242	Release of Neurotransmitters. , 2004, , 197-244.		5
243	Dysfunction of the brain calcium channel CaV2.1 in absence epilepsy and episodic ataxia. Brain, 2004, 127, 2682-2692.	7.6	191
244	Comment on "Role of NMDA Receptor Subtypes in Governing the Direction of Hippocampal Synaptic Plasticity". Science, 2004, 305, 1912b-1912b.	12.6	16
245	Heterogeneity and Specificity of Presynaptic Ca2+ Current Modulation by mGluRs at Individual Hippocampal Synapses. Cerebral Cortex, 2004, 14, 748-758.	2.9	31
246	NR2B-Containing Receptors Mediate Cross Talk among Hippocampal Synapses. Journal of Neuroscience, 2004, 24, 4767-4777.	3.6	179
247	Endogenous Zinc Inhibits GABAA Receptors in a Hippocampal Pathway. Journal of Neurophysiology, 2004, 91, 1091-1096.	1.8	88
248	Tonically active GABAA receptors: modulating gain and maintaining the tone. Trends in Neurosciences, 2004, 27, 262-269.	8.6	698
249	GABA and GABAA receptors at hippocampal mossy fibre synapses. European Journal of Neuroscience, 2003, 18, 931-941.	2.6	87
250	GABA uptake regulates cortical excitability via cell typeâ€“specific tonic inhibition. Nature Neuroscience, 2003, 6, 484-490.	14.8	366
251	Neurological phenotype and synaptic function in mice lacking the CaV1.3 Î± subunit of neuronal L-type voltage-dependent Ca2+ channels. Neuroscience, 2003, 120, 435-442.	2.3	71
252	GABAA Receptors at Hippocampal Mossy Fibers. Neuron, 2003, 39, 961-973.	8.1	142

#	Article	IF	Citations
253	Admission to neurological intensive care: who, when, and why?. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 2iii-9.	1.9	26
254	Silent synapses: what are they telling us about long-term potentiation?. Philosophical Transactions of the Royal Society B: Biological Sciences, 2003, 358, 727-733.	4.0	38
255	Plasticity of GABA_BReceptor-Mediated Heterosynaptic Interactions at Mossy Fibers After Status Epilepticus. Journal of Neuroscience, 2003, 23, 11382-11391.	3.6	58
256	Epilepsy genetics. Drugs of Today, 2003, 39, 725.	2.4	0
257	Outcome of ventilatory support for acute respiratory failure in motor neurone disease. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 752-756.	1.9	60
258	The neuronal channelopathies. Brain, 2002, 125, 1177-1195.	7.6	161
259	Genetics of epilepsy. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 32ii-35.	1.9	14
260	Relative picrotoxin insensitivity distinguishes ionotropic GABA receptor-mediated IPSCs in hippocampal interneurons. Neuropharmacology, 2002, 43, 726-736.	4.1	23
261	Neurological disorders caused by inherited ion-channel mutations. Lancet Neurology, The, 2002, 1, 157-166.	10.2	66
262	Glutamatergic Modulation of GABAergic Signaling Among Hippocampal Interneurons: Novel Mechanisms Regulating Hippocampal Excitability. Epilepsia, 2002, 43, 174-178.	5.1	59
263	Do Mossy Fibers Release GABA?. Epilepsia, 2002, 43, 196-202.	5.1	26
264	Functional characterization of compound heterozygosity for GlyRÎ±1 mutations in the startle disease hyperekplexia. European Journal of Neuroscience, 2002, 16, 186-196.	2.6	28
265	Variable K + channel subunit dysfunction in inherited mutations of KCNA1. Journal of Physiology, 2002, 538, 5-23.	2.9	60
266	Monosynaptic GABAergic Signaling from Dentate to CA3 with a Pharmacological and Physiological Profile Typical of Mossy Fiber Synapses. Neuron, 2001, 29, 703-715.	8.1	189
267	Presynaptic Kainate Receptors in the Hippocampus. Neuron, 2001, 32, 561-564.	8.1	81
268	Human epilepsy associated with dysfunction of the brain P/Q-type calcium channel. Lancet, The, 2001, 358, 801-807.	13.7	340
269	Kainate receptor-dependent axonal depolarization and action potential initiation in interneurons. Nature Neuroscience, 2001, 4, 718-723.	14.8	142
270	The Inherited Episodic Ataxias: How Well Do We Understand the Disease Mechanisms?. Neuroscientist, 2001, 7, 80-88.	3.5	25

#	Article	IF	Citations
271	The role of mammalian ionotropic receptors in synaptic plasticity: LTP, LTD and epilepsy. Cellular and Molecular Life Sciences, 2000, 57, 1551-1561.	5.4	73
272	Modulation of GABAergic Signaling among Interneurons by Metabotropic Glutamate Receptors. Neuron, 2000, 25, 663-672.	8.1	170
273	Spillover and synaptic cross talk mediated by glutamate and GABA in the mammalian brain. Progress in Brain Research, 2000, 125, 339-351.	1.4	82
274	A novel mutation in the human voltage-gated potassium channel gene (Kv1.1) associates with episodic ataxia type 1 and sometimes with partial epilepsy. Brain, 1999, 122, 817-825.	7.6	314
275	Synaptically released glutamate reduces gamma -aminobutyric acid (GABA)ergic inhibition in the hippocampus via kainate receptors. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 9932-9937.	7.1	113
276	Synaptic and extrasynaptic roles of glutamate in the mammalian hippocampus. Acta Physiologica Scandinavica, 1999, 166, 79-83.	2.2	11
277	Febrile convulsions: a 'benign' condition?. Nature Medicine, 1999, 5, 871-872.	30.7	23
278	Neither too loud nor too quiet. Nature, 1999, 399, 111-112.	27.8	12
279	Functional Characterization of a Novel Mutation in KCNA1 in Episodic Ataxia Type 1 Associated with Epilepsy. Annals of the New York Academy of Sciences, 1999, 868, 442-446.	3.8	28
280	Role of the synaptic microenvironment in functional modification of synaptic transmission. Neurophysiology, 1999, 31, 79-81.	0.3	3
281	AMPA Receptor Attrition in Long-Term Depression. Neuron, 1999, 24, 288-290.	8.1	7
282	Variable Loudness at Individual Excitatory Synapses. Neuron, 1999, 22, 206-207.	8.1	0
283	Hippocampal synapses: do they talk to their neighbours?. Trends in Neurosciences, 1999, 22, 382-388.	8.6	115
284	Extracellular glutamate diffusion determines the occupancy of glutamate receptors at CA1 synapses in the hippocampus. Philosophical Transactions of the Royal Society B: Biological Sciences, 1999, 354, 395-402.	4.0	55
285	Extrasynaptic glutamate spillover in the hippocampus: evidence and implications. Trends in Neurosciences, 1998, 21, 8-14.	8.6	302
286	A tortuous and viscous route to understanding diffusion in the brain. Trends in Neurosciences, 1998, 21, 469-470.	8.6	19
287	Activation of AMPA, Kainate, and Metabotropic Receptors at Hippocampal Mossy Fiber Synapses. Neuron, 1998, 21, 561-570.	8.1	187
288	Geometric and viscous components of the tortuosity of the extracellular space in the brain. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 8975-8980.	7.1	169

#	Article	IF	Citations
289	Long-term potentiation and dual-component quantal signaling in the dentate gyrus. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 4702-4707.	7.1	62
290	Extrasynaptic Glutamate Diffusion in the Hippocampus: Ultrastructural Constraints, Uptake, and Receptor Activation. Journal of Neuroscience, 1998, 18, 3158-3170.	3.6	405
291	Endogenous Neurotrophin-3 Regulates Short-Term Plasticity at Lateral Perforant Pathâ€“Granule Cell Synapses. Journal of Neuroscience, 1998, 18, 8730-8739.	3.6	59
292	Extrasynaptic Glutamate Spillover in the Hippocampus: Dependence on Temperature and the Role of Active Glutamate Uptake. Neuron, 1997, 18, 281-293.	8.1	380
293	LTP of AMPA and NMDA Receptorâ€“Mediated Signals: Evidence for Presynaptic Expression and Extrasynaptic Glutamate Spill-Over. Neuron, 1996, 17, 461-474.	8.1	252
294	Brainstem encephalopathy with stimulus-sensitive myoclonus leading to respiratory arrest, but with recovery: A description of two cases and review of the literature. Movement Disorders, 1996, 11, 715-718.	3.9	6
295	The site of expression of NMDA receptor-dependent LTP: New fuel for an old fire. Neuron, 1995, 15, 997-1002.	8.1	144
296	Amplitude fluctuations of. Neuron, 1994, 12, 1111-1120.	8.1	316
297	Ca2+ Entry via postsynaptic voltage-sensitive Ca2+ channels can transiently potentiate excitatory synaptic transmission in the hippocampus. Neuron, 1992, 9, 1175-1183.	8.1	261
298	Long-term potentiation is associated with increases in quantal content and quantal amplitude. Nature, 1992, 357, 240-244.	27.8	281
299	Quantal analysis using maximum entropy noise deconvolution. Journal of Neuroscience Methods, 1992, 44, 47-57.	2.5	18
300	Statistical and Computational Methods for Quantal Analysis of Synaptic Transmission. Methods in Neurosciences, 1992, , 363-375.	0.5	0
301	Monosynaptic EPSPs in cat lumbosacral motoneurones from group Ia afferents and fibres descending in the spinal cord.. Journal of Physiology, 1989, 412, 43-63.	2.9	25
302	Reduction by baclofen of monosynaptic EPSPs in lumbosacral motoneurones of the anaesthetized cat.. Journal of Physiology, 1989, 416, 539-556.	2.9	71
303	The effects of lesions on autogenetic inhibition in the decerebrate cat.. Journal of Physiology, 1989, 419, 611-625.	2.9	6
304	Applications of the expectation-maximization algorithm to quantal analysis of postsynaptic potentials. Journal of Neuroscience Methods, 1989, 30, 231-245.	2.5	44
305	Reduction by general anaesthetics of group Ia excitatory postsynaptic potentials and currents in the cat spinal cord.. Journal of Physiology, 1989, 412, 277-296.	2.9	54
306	Autogenetic inhibition from contraction receptors in the decerebrate cat.. Journal of Physiology, 1989, 419, 589-610.	2.9	5

#	Article	IF	Citations
307	Disorders of Consciousness, Intensive Care Neurology and Sleep. , 0, , 723-769.		1
308	Channelopathies. , 0, , 121-135.		0